Spots Global Cancer Trial Database for A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
Official Title: An Open-label, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in Advanced HER-2 Positive Breast Cancer Patients Previously Treated With Trastuzumab and TKIs (Magic-009)
Study ID: NCT05263869
Conditions
Interventions
Study Description
Brief Summary: The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2 positive breast cancer with liver metastases.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Contact Details
Name: Zefei Jiang, MD
Affiliation: Fifth Medical Center of PLA General Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Qiang Liu, MD
Affiliation: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
